STAAR Surgical Announces $30 Million Share Buyback

Staar Surgical ( (STAA) ) has provided an update.

On May 16, 2025, STAAR Surgical announced a $30 million share repurchase program, reflecting the board’s confidence in the company’s future and commitment to shareholder value. Additionally, on May 14, 2025, STAAR received approval from China’s National Medical Products Administration for its EVO+ Toric Implantable Collamer Lens, enhancing its market presence in China and aligning with its strategic priorities.

The most recent analyst rating on (STAA) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.

Spark’s Take on STAA Stock

According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.

STAAR Surgical currently faces significant challenges with declining revenues, negative cash flow, and profitability issues, especially impacted by sales decline in China. The technical analysis shows uncertainty with no strong trends, while valuation concerns arise from negative earnings. Leadership changes and strategic initiatives offer potential for improvement, but immediate financial recovery remains uncertain.

To see Spark’s full report on STAA stock, click here.

More about Staar Surgical

STAAR Surgical is a global leader in implantable phakic intraocular lenses, offering vision correction solutions that reduce or eliminate the need for glasses or contact lenses. Since 1982, the company has focused on ophthalmic surgery, designing and marketing advanced Implantable Collamer Lenses (ICLs) using proprietary biocompatible Collamer material. Headquartered in Lake Forest, California, STAAR operates research, development, manufacturing, and packaging facilities in California and Switzerland.

Average Trading Volume: 1,074,318

Technical Sentiment Signal: Sell

Current Market Cap: $863.2M

Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.